Clearside Biomedical (CLSDQ) Proxy Filing summary

Executive summary

• A special meeting is scheduled for August 29, 2025, to vote on a reverse stock split and corresponding reduction in authorized shares, with the split ratio to be determined by the board within a 1-for-5 to 1-for-15 range.

• The reverse stock split aims to increase the per-share trading price to maintain Nasdaq Global Market listing, following a notice of non-compliance with the $1.00 minimum bid price requirement.

• If approved, the board will have discretion to implement the split within 12 months or abandon it if not deemed in the best interests of the company and shareholders.

• The split will affect all shareholders uniformly, with no material change to percentage ownership or voting power, and cash will be paid in lieu of fractional shares.

• The board recommends a vote in favor of the proposal.

Voting matters and shareholder proposals

• The sole proposal is to approve alternate amendments for a reverse stock split and authorized share reduction, with the board empowered to select the ratio.

• A majority of votes cast is required for approval; abstentions have no effect, and broker non-votes are not expected as the matter is considered routine.

• Shareholders of record as of July 28, 2025, are eligible to vote, with multiple voting methods available (online, phone, mail, or in person).

• Stockholder proposals for the 2026 annual meeting must be submitted by December 19, 2025, for inclusion in proxy materials.

Shareholder rights and capital structure

• The reverse split will reduce both outstanding and authorized shares proportionally, with the new authorized share count ranging from 26,666,666 to 80,000,000 depending on the split ratio.

• No change to the par value or rights of common stock; the split is not intended as a going private transaction.

• The board retains discretion to implement or abandon the split and may use the increased authorized but unissued shares for corporate purposes.

• The split may have anti-takeover effects by increasing the proportion of authorized but unissued shares, though this is not the intent.